Episode 402: 410. When You Shouldn't Double Down But Instead Hit for Another

This massive meta-analysis of 484 randomized, double-blind, placebo-controlled trials (104,176 participants) quantified the blood pressure–lowering effects of major antihypertensive drug classes and their combinations. It introduces a new intensity-based classification system and an online calculator to predict BP-lowering efficacy based on drug, dose, and baseline BP.

Study Design:

• 484 trials, 104,176 participants
• 5 major drug classes: ACE inhibitors, ARBs, β-blockers, calcium channel blockers (CCBs), and diuretics
• Focus: Placebo-corrected reduction in systolic BP (SBP)
• Mean baseline BP: 154/100 mm Hg
• Mean follow-up: 8.6 weeks

Key Findings

Monotherapy (Standard Dose):

• Average SBP reduction: 8.7 mm Hg
• By class:
  • ACE inhibitors: 6.8 mm Hg
  • ARBs: 8.5 mm Hg
  • β-blockers: 8.9 mm Hg
  • CCBs: 9.5 mm Hg
  • Thiazide diuretics: 10.8 mm Hg

Dose Doubling:

• Adds ~1.5 mm Hg SBP reduction (except β-blockers, which add only ~0.5 mm Hg)

Dual Therapy (Standard Dose of Each):

• Average SBP reduction: 14.9 mm Hg
• Dose doubling adds ~2.5 mm Hg more

Triple Therapy:

• SBP reduction: Up to 22.5 mm Hg (quadruple therapy even higher in one trial)